IL1B and prostate carcinoma: This discrepancy, which is to be expected considering the inevitable differences between established cell lines and human samples, suggests that methylation of multiple CpG sites on the IL1β promoter and gene body modulates the transcription of this cytokine in prostate cancer cells.